Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence-Reference-Cited by-同舟云学术

Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence

Published:2023-12 Issue: Volume:147 Page:106587
ISSN:1368-8375
Container-title:Oral Oncology
language:en
Short-container-title:Oral Oncology

Author:

Harrington K.J.,Cohen E.E.W.,Soulières D.,Dinis J.,Licitra L.,Ahn M.-J.,Soria A.,Machiels J.-P.,Mach N.,Mehra R.,Burtness B.,Swaby R.F.,Lin J.,Ge J.,Lerman N.,Tourneau C. Le

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Oral Surgery

Reference25 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J. Clin.,2021

2. Head and neck cancer;Chow;N. Engl. J. Med.,2020

3. New developments in the management of head and neck cancer – impact of pembrolizumab;Saleh;Ther. Clin. Risk Manag.,2018

4. Decision making in the management of recurrent head and neck cancer;Ho;Head Neck,2014

5. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC);Cohen;J. Immunother. Cancer,2019

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Precision Medicine and Clinical Trials in Advanced and Metastatic Oral Cancer;Journal of Maxillofacial and Oral Surgery;2024-06-17

2. Decoding the research landscape of drug resistance and therapeutic approaches in head and neck cancer: a bibliometric analysis from 2000 to 2023;Frontiers in Pharmacology;2024-04-05

3. Exploring the function of myeloid cells in promoting metastasis in head and neck cancer;Exploration of Targeted Anti-tumor Therapy;2024-02-19